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NK-cell resistance to transduction is a major technical hurdle for developing NK-cell
immunotherapy. By using Baboon envelope pseudotyped lentiviral vectors (BaEV-LVs)
encoding eGFP, we obtained a transduction rate of 23.0 ± 6.6% (mean ± SD) in
freshly-isolated human NK-cells (FI-NK) and 83.4 ± 10.1% (mean ± SD) in NK-cells
obtained from the NK-cell Activation and Expansion System (NKAES), with a sustained
transgene expression for at least 21 days. BaEV-LVs outperformed Vesicular Stomatitis
Virus type-G (VSV-G)-, RD114- and Measles Virus (MV)- pseudotyped LVs (p < 0.0001).
mRNA expression of both BaEV receptors, ASCT1 and ASCT2, was detected in
FI-NK and NKAES, with higher expression in NKAES. Transduction with BaEV-LVs
encoding for CAR-CD22 resulted in robust CAR-expression on 38.3 ± 23.8% (mean
± SD) of NKAES cells, leading to specific killing of NK-resistant pre-B-ALL-RS4;11
cell line. Using a larger vector encoding a dual CD19/CD22-CAR, we were able to
transduce and re-expand dual-CAR-expressing NKAES, even with lower viral titer. These
dual-CAR-NK efficiently killed both CD19KO- and CD22KO-RS4;11 cells. Our results
suggest that BaEV-LVs may efficiently enable NK-cell biological studies and translation
of NK-cell-based immunotherapy to the clinic.
Keywords: NK-cell transduction, baboon retrovirus envelope pseudotyped lentivectors, chimeric antigen receptor,
NK amplification and expansion system (NKAES), cytotoxicity
INTRODUCTION
The relative resistance of NK cells to transduction hampers the study of NK-cell biology and the
development of NK cell-based immunotherapy. VSV-G-LVs, classically used to generate chimeric
antigen receptor (CAR)-T cells (1), do not efficiently transduce NK-cells. RD114-pseudotype viral
vectors represent an attractive alternative since their entry receptor, the sodium-dependent neutral
amino acid transporter (ASCT2) (2, 3), is widely expressed in the hematopoietic lineage (4).
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However, despite encouraging initial report, RD114-based viral
vectors only transduce NK-cells at low levels. Nevertheless, they
recently enabled clinical development of cord-blood derived
CAR-NK-cells (5). To fill the need for an efficient method for
transducing NK cells, we investigated alternative pseudotyping
proteins. Since the Baboon envelope pseudotyped lentiviral
vector (BaEV-LV) binds ASCT1 (6) in addition to ASCT2 for
viral entry, we assessed their efficacy to transduce NK-cells
for therapeutic purposes. As observed independently by Bari
et al. (7) our data demonstrate the efficacy of BaEV-LV in NK-
cell transduction.
METHODS
Cells and Culture Condition
Blood samples were obtained from healthy volunteers after
informed consent (IRB-approved protocol #CER-3527). NK-
cells were enriched from PBMC using a CD56-positive selection
kit (Stemcell Technologies, Canada). NK cells were expanded
using the Amplification and Expansion System (NKAES)
with irradiated K562mbIL21 or K562mbIL15 feeder cells as
described (8, 9). Alternatively, NK-cells were amplified using
NK-MACS Medium (130-114-429, Miltenyi) system according
to manufacturer’s instructions. RS4;11 (ATCC) CD19/22KO
were generated using purified Cas9 protein and two gRNA
targeting CD19 or CD22 (Integrated DNA Technologies).
CD19KO and/or CD22KO cells were FACS-sorted based on
loss of surface marker expression. Cells were cultured in
DMEM (Wisent) or RPMI1640 supplemented with 10% FCS and
penicillin/streptomycin (Gibco). Media were supplemented with
100 UI/mL IL-2 (Proleukin—Novartis Pharmaceuticals, Canada)
for NK-cell cultures.
Plasmids and Viral Production
An UCOE sequence (10) was added to the lentiviral vector
pHRSIN-SFFV-eGFP (11) upstream of the SFFV promoter to
produce pHUS-GFP vector. For the CAR-expression vector, GFP
in pHUS-GFP was replaced by an anti-CD22 CAR (m971 ScFv)
fused to 28BBz constructed from 28z and BBz (Dr. Orentas,
National Cancer Institute) (12). For the dual CAR-expression
vector, the GFP-cassette was replaced by 2nd-generation anti-
CD19 and anti-CD22 CARs, separated by a self-cleaving T2A
peptide (Figure 3A). The pMD2.G (VSV-G) was a gift from
Didier Trono (Addgene plasmid#12259; http://n2t.net/addgene:
12259; RRID:Addgene_12259) and pLTR-RD114A (13) (RD114)
was a gift from Jakob Reiser (Addgene plasmid#17576; http://n2t.
net/addgene:17576; RRID:Addgene_17576). The Measles virus
(MV-LV) and BaEVRLess envelope plasmids were used as
previously described (6). Titration was performed on HEK293T
cells (ATCC) using serial virus dilutions (6).
Viral Transduction
NKAES were transduced after 1 week of expansion. One day
before transduction, a 12-well plate was coated with RetroNectin
(Takara). The following day, concentrated vectors at indicated
multiplicity of infection (MOI), were added to coated plates for
4 h at 37◦C. Then NK cells were seeded in these wells in IL-2-
supplemented medium and protamine sulfate (Pharmaceutical
Partners of Canada Inc.) (8 ug/mL). The plates were then
centrifuged at 1,000 g for 1 h and incubated at 37◦C overnight.
The next day, IL-2-supplemented medium was added to each
well. Transduction was assessed on day 3 or day 5 after
transduction for NKAES and freshly isolated NK-cells (FI-
NK), respectively.
Flow Cytometry
All samples were stained with anti-CD56-APC, anti-CD3-FITC
(Biolegend) and 7AAD (BD Biosciences). Transgene expression
was detected by flow cytometry on 7AAD− CD56(-APC)+ CD3(-
PE)− cells (Biolegend). For NK-cell receptor detection, samples
were stained with DAPI, CD56-BV711, CD16-BV786, NKp30-
AF647, NKp44-PE, NKp46-BV421 (Biolegend), NKG2D-APC
(BD Biosciences), and NKG2A-PE (Miltenyi Biotec). CD3-
BV650 and CD19-APC-Cy7 (Biolegend) markers were used as
a gating exclusion strategy for the NK cell staining. Receptor
expression was assessed on DAPI− CD56(-BV711)+ CD3(-
BV650)− cells. To detect CAR-expression, cells were incubated
with 2µl Siglec2(CD22)-Fc chimera (50mg/ml, R&D) for 30min
at 4◦C, washed and stained with anti-Fc-PE (Jackson Immune).
Cytotoxicity Assay
Cytotoxicity was assessed 24 h after cell contact by flow
cytometry. Targets cells were loaded with PKH26 dye (Sigma-
Aldrich) according to the manufacturer’s directives and seeded
in 96 well round bottom plates. Effector cells were then added
at different effector:target ratios and medium alone was added
to control wells. Before acquisition, 7AAD was added to each
well to discriminate dead cells. The cytotoxicity was calculated as:
Cytotoxicity (%)= [1-live targets (sample)/live targets (control)]
× 100%.
mRNA Quantification
RNA-seq expression studies were independently performed in
two laboratories (Accession #GSE128696, #GSE129044). For the
FI-NK vs. IL-21-NKAES/IL-15-NKAES comparisons, extraction
of total RNA was done using the RNeasy mini kit (Qiagen) and
Total RNA Purification Plus Kit (Norgen Biotek), respectively.
The quality of RNA was verified with 2100 Bioanalyzer (Agilent)
prior to preparation of sequencing libraries with the TruSeq RNA
Sample Prep v2 Kit. Quality of libraries was verified via Agilent
4200 Tapestation using a High Sensitivity D1000 ScreenTape
Assay kit. For the IL-15 NKAES analysis, approximately 60–
80 million paired-end 150 bp sequence reads per library were
generated, whereas for the IL-21 NKAES analysis, 30 million
single-end 101 bp sequence reads per library were generated,
both using Illumina HiSeq4000 platform. Kallisto, an RNA
quantification program based on pseudoalignment was used to
obtain read count estimates per gene (14). The differential gene
expression analysis was done using DESeq2, edgeR, and limma
R packages.
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Statistical Analyses
Statistical analyses were performed using GraphPad PRISM 8.0
(GraphPad Software). Statistical significance was determined
by one-way or 2-way ANOVA with multiple testing and
Bonferoni correction or using simple multiple T-tests with
Holm-Sidak correction.
Study Approval
Blood samples were obtained from healthy volunteers after
informed and written consent. The study was approved by the
institutional ethical board of the CHU Sainte-Justine (approved
protocol #CER-3527).
RESULTS AND DISCUSSION
We first transduced NK cells expanded using the Amplification
and Expansion System (NKAES) and freshly isolated NK-cells
(FI-NK) with an eGFP-encoding LV and observed that in both
cases, BaEV-LVs outperformed VSV-G-, MV-, and RD114- LVs
(Figure 1A, 83.4 % mean transduction rate vs. 15.7, 13.7, and
37.8% for NKAES, p < 0.0001, and 23.0% vs. 10.4%, 2.1 and
7.8% for FI-NK, p< 0.0001, respectively). Themean fluorescence
intensity (MFI) of GFP after transduction in NK cells was similar
for BAEV, VSV-G and RD114 and significantly lower for MV-
LV in NKAES (Figure 1B). The mean transduction rate with
FIGURE 1 | BaEV-LV efficiently transduces expanded (NKAES) and freshly isolated NK-cells (FI-NK). (A) Transduction of NK amplification and Expansion System
(NKAES) cells (K562mbIL21 system, left panel-in blue) or FI-NK (right panel- in red) using VSV-G (n = 3 and n = 6), Measles virus (MV; n = 3 each), RD114 (n = 7 and
n = 6) or BaEV (n = 8 and n = 12) envelope pseudotyped LVs encoding eGFP at a MOI of 10. Fluorescence was evaluated by flow cytometry (****P < 0.0001 for both
NKAES and FI-NK; one-way ANOVA test with multiple testing and Bonferroni correction). On the middle panels are shown representative flow cytometry plots of GFP
expression after NKAES-cell transduction with BaEV-LVs (untransduced, middle left; transduced, middle right). (B) Mean fluorescence intensity for GFP expression in
NKAES cells (K562mbIL21 system, left panel-in blue) or FI-NK (right panel-in red) using VSV-G (n = 3 and n = 6), Measles virus (MV; n = 3 each), RD114 (n = 3 and n
= 6) or BaEV (n = 8 and n = 12) envelope pseudotyped LVs encoding eGFP. Fluorescence was evaluated by flow cytometry (***p < 0.001 and p = 0.0882 for NKAES
and FI-NK respectively; one-way ANOVA test with multiple testing and Bonferroni correction). (C) Transduction of NKAES (left panel-blue; n = 5) or FI-NK (right
panel-red; n = 3) using BaEV-LV-encoding eGFP at various multiplicities of infection (MOI) was measured by fluorescence. (D) BaEV-LV transduction of NKAES using
K562mbIL21 or K562mbIL15 irradiated feeder cells (n = 4), or using the NK-MACS Medium (p = 0.4265; one-way ANOVA test with multiple testing and Bonferroni
correction, n = 3). (E) Left panel: Flow cytometry plot representative of NK cell markers expression after NK-cell transduction with BaEV-LVs. Transduced (GFP
positive) NKAES are in blue and non-transduced (GFP negative) NKAES are in red. Right panel: Mean fluorescence intensity for NK cell markers for untouched and
BaEV-LV treated NKAES. BaEV-LV treated NKAES were gated according to GFP to separate transduced (GFP positive) or non-transduced (GFP negative) NKAES (p
= 0.2994; 2-way ANOVA test with multiple testing and Bonferroni correction, n = 4). Data are presented as the mean ± SEM. For all experiments, NKAES and FI-NK
were assessed at day 3 or day 5 post-transduction, respectively.
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BaEV-LVs was higher than 60% for NKAES even at low MOI
of 1, and ranged from 12.4% at a MOI of 1 to a maximum
of 27.2% at a MOI of 10 for FI-NK (Figure 1C). Transgene
expression persisted over time after transduction with BaEV-
LVs, although a decrease was observed from 70.6 to 61.4% in 14
days for NKAES (p = 0.06). Transduced FI-NK could be easily
amplified after transduction (not shown). High transduction
rates were also observed after NK-cell expansion on K562-
mbIL15-41BBL feeder cells (8) or feeder-free NKMACSmedium
(15) (Figure 1D).
NK-cell receptors expression was assessed on untouched
and BaEV-LV treated NKAES, which were either transduced
(GFP+) or non-transduced (GFP-) (Figure 1E). There was no
difference in CD56, CD16, NKG2D, NKG2A, NKp30, NKp44,
and NKp46 receptors expression, suggesting that those markers
are neither linked to the transduction efficiency, nor affected
by the transduction (Figure 1E), unlike what has been recently
reported (7). This difference could be attributed to the different
expansion system used in our study.
The number of recovered living cells in both NKAES and FI-
NKwas preserved after transduction with BaEV-LVs (Figure 2A)
although MV-LV transduction on NKAES yielded more living
recovered cells than BaEV-LV transduction (p < 0.05). Although
the percentage of dead cells in culture was low for all conditions
FIGURE 2 | BaEV-LV transduction does not alter the phenotype or function of NK cells. (A) Viability of NKAES (left panel; n = 3) or FI-NK (right panel; VSV-G and
MV-LV n = 6, RD114 n = 3, BaEV n = 9) with different LVs was assessed via the ratio of living (7-AAD-negative) cells in the culture normalized to the initial number of
cells before transduction (*p < 0.05 and p = 0.141 for NKAES and FI-NK, respectively; one-way ANOVA test with multiple testing and Bonferroni correction). (B) Cell
death, assessed by the percentage of 7-AAD positive cells, of NKAES (left panel; VSV-G, MV-LV and RD114 n = 3, BaEV n = 8) or FI-NK (right panel; VSV-G and
RD114 n = 6, MV-LV n = 3, BaEV n = 12) with different LVs. Percentage of 7-AAD positive cells was calculated by flow cytometry after debris exclusion (*p < 0.05
and **p < 0.01 for NKAES, and p = 0.14 for FI-NK; one-way ANOVA test with multiple testing and Bonferroni correction). (C) Flow cytometry plot showing the gating
strategy used in cytotoxicity experiments. Cells were first gated on forward and side scatter (FSC-A, SSC-A) and then the live 7-AAD negative cells were selected.
Finally, PKH26 stained target cells were gated to numerate the remaining cells. (D) Cytolytic function of BaEV-LV-transduced vs. untransduced NKAES cells against
K562 target cells. Data represent the percentage of target lysis, assessed by flow cytometry relative to the effector/target ratio and normalized to targets alone. (p =
0.4012, 2-way ANOVA test with multiple testing and Bonferroni correction, n = 3). (E) Quantitative expression of the viral receptors mRNAs assessed by RNA-seq in
NKAES expanded with K562mbIL21 and in FI-NK-cells (n = 4, **p < 0.01, multiple T-tests with Holm-Sidak correction). (F) Quantitative expression of the viral
receptors mRNAs assessed by RNA-seq in NKAES expanded with K562mbIL15 and in FI-NK-cells (n = 4, *p < 0.05, **p < 0.01, ***p < 0.001, multiple T-tests with
Holm-Sidak correction). Data are presented as the mean ± SEM, except where noted. For all experiments, NKAES and FI-NK were assessed at day 3 or day 5
post-transduction, respectively.
Frontiers in Immunology | www.frontiersin.org 4 December 2019 | Volume 10 | Article 2873
Colamartino et al. Efficient and Robust NK-Cell Transduction With BaEV
(Figure 2B), it was higher in NKAES transduced with MV-
LV and RD114-LV as compared to BaEV (p < 0.01 and p <
0.05, respectively). Together these results suggest that BaEV-LV
transduction did not affect viability nor NK-cell proliferation.
We then assessed whether NK-cell cytotoxic function was
preserved after BaEV-LV transduction and confirmed that the
cytotoxicity of eGFP-transduced NKAES cells against K562 cells
was equivalent to non-transduced NKAES (Figures 2C,D).
RNAseq analyses of both FI-NK and NKAES showed that
ASCT1 and ASCT2 mRNAs were detected at significantly higher
frequency in both IL-15- and IL-21-NKAES than in FI-NK
(Figures 2E,F), which may explain the higher transduction rate
of NKAES. These data were confirmed by qPCR (not shown).
Also, the expression of both BaEV receptors by NK cells
may explain the higher transduction efficacy of BaEV-LVs as
compared to RD114 which use only one of those receptors.
CAR-expressing NK-cells represent one of the most relevant
clinical applications of efficient NK-cell transduction. We first
tested a single 3rd generation CAR construct recognizing CD22
(Figure 3A). We obtained a transduction rate of 38.3% ± 23.8%
(mean ± SD) of NKAES and a high sustained level of CAR-
expression (58.4% ± 7.8%; mean ± SD) after sorting and re-
expansion (Figures 3B,C). We demonstrated that CD22-CAR-
NK-cells efficiently and specifically killed B-ALL RS4;11 target
cells, which were resistant to untransduced NKAES (Figure 3D).
We could obtain 5 × 108 CAR-expressing cells from 5 × 105
transduced cells after an expansion of 14 days (not shown).
Since transgene size affects transduction efficacy (16, 17), we
FIGURE 3 | BaEV-LVs allow robust CAR-expression in NK-cells. (A) Schematic representation of the different LVs used for NK-cell transduction using BaEV-LV
(relative scale according to size in base pairs). (B) Percentage of transduced NKAES cells using BaEV-LVs coding for an anti-CD22 CAR, assessed at day 3 after
transduction (“transduced”; n = 15) and after sorting and 1 week of re-expansion (“sorted/expanded”; n = 3). (C) Flow cytometry plot representative of CAR-CD22
expression after NK-cell transduction with BaEV-LVs. (D) Cytotoxic assays of NKAES (either untransduced or CAR-CD22-NK-cells) against either parental (WT; n = 7)
or CD19/22KO-RS4;11 cells (B-ALL; n = 2) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; 2-way ANOVA test with multiple testing and Bonferroni correction).
(E) Percentage of transduced NKAES cells using BaEV-LVs coding for the dual CAR assessed at day 3 after transduction (“transduced”; n = 9) and after sorting and 2
weeks of re-expansion (“sorted/expanded”; n = 3). (F) Flow cytometry plot representative of dual CAR expression after NK-cell transduction with BaEV-LVs. (G)
Cytotoxic assays using NKAES cells transduced with a dual CAR (left panel) or untransduced NKAES (right panel) against either parental (WT; n = 8 each), CD19KO (n
= 3 for untransduced, n = 4 for CAR transduced), CD22KO (n = 1 for untransduced, n = 2 for CAR transduced) or CD19/CD22KO RS4;11 B-ALL cells (n = 3 for
untransduced, n = 5 for CAR transduced). Data are presented as the mean ± SEM.
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also tested a dual CAR-expressing vector with two independent
chains recognizing CD19 and CD22. The length of the dual
CAR-CD22/19 LV had a significant impact on virus production
and NK transduction was lower (23.1 ± 20.5%; mean ± SD)
(Figures 3E,F). However, we were able to sort and re-expand
these dual-CAR-transduced NK-cells for 2 weeks, keeping the
transgene expression at a high level (79.0 ± 8.7%; mean ±
SD) (Figure 3E). These CAR-CD22/19-NKAES killed efficiently
CD19KO or CD22KO-RS4;11 cells, which suggest that this strategy
could be efficient for preventing tumor evasion to CAR therapy
(18, 19) (Figure 3G).
In this study we showed that BaEV-LV is an efficient and
robust tool to transduce NK cells. As a proof-of-concept, we
generated large numbers of engineered CAR-NK-cells, which
induced specific killing of antigen-bearing cancer cells, even
with a large dual CAR-LV construct. This technique was robust
and reproducible in different expansion systems, including a
feeder-cell-free system. The higher level of transduction could
open up possibilities for the use of this method to generate
an immunotherapeutic product. The prevalence of receptors, as
seen by RNAseq, could explain the difference seen between the
transduction of activated and resting NK cells. The fact that
activated NK cells express both entry receptors at high level
could also explain why this envelope protein is more efficient
than the others. The development of such a tool could have a
major impact on both basic research of NK-cell biology study and
NK-cell-based immunotherapy.
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